Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema

Arthur G Chung,P. Keith

DOI: https://doi.org/10.1186/1710-1492-6-S2-P28

2010-11-04

Abstract:

What problem does this paper attempt to address?

A renal transplant patient with a solitary plasmacytoma in the oral cavity.

Y. Caliskan,S. Ozturk,M. Demirturk,O. Ozkan,H. Yazıcı,T. Ecder,A. Turkmen,M. Sever

DOI: https://doi.org/10.1093/NDT/GFK053

2006-06-01

Abstract:
Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis

Emma L. Twait,Jen-Hao Wu,Maria Kamarioti,Maartje Basten,Wiesje M. van der Flier,Lotte Gerritsen,Mirjam I. Geerlings

DOI: https://doi.org/10.1038/s41398-024-02739-9

2024-01-16

Translational Psychiatry

Abstract:Several lines of evidence have indicated that depression might be a prodromal symptom of Alzheimer's disease (AD). This systematic review and meta-analysis investigated the cross-sectional association between amyloid-beta, one of the key pathologies defining AD, and depression or depressive symptoms in older adults without dementia. A systematic search in PubMed yielded 689 peer-reviewed articles. After full-text screening, nine CSF studies, 11 PET studies, and five plasma studies were included. No association between amyloid-beta and depression or depressive symptoms were found using cerebrospinal fluid (CSF) (0.15; 95% CI: −0.08; 0.37), positron emission topography (PET) (Cohen's d: 0.09; 95% CI: −0.05; 0.24), or plasma (−0.01; 95% CI: −0.23; 0.22). However, subgroup analyses revealed an association in plasma studies of individuals with cognitive impairment. A trend of an association was found in the studies using CSF and PET. This systematic review and meta-analysis suggested that depressive symptoms may be part of the prodromal stage of dementia.

psychiatry
Gastric cytology.

R. Schade

Proceedings of the Royal Society of Medicine

Abstract:
Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression

Nikias Siafarikas,Bjørn-Eivind Kirsebom,Deepak P. Srivastava,Cecilia M. Eriksson,Eirik Auning,Erik Hessen,Geir Selbaek,Kaj Blennow,Dag Aarsland,Tormod Fladby

DOI: https://doi.org/10.1038/s41598-021-99794-9

IF: 4.6

2021-10-13

Scientific Reports

Abstract:Abstract To explore markers for synaptic function and Alzheimer disease (AD) pathology in late life depression (LLD), predementia AD and normal controls (NC). A cross-sectional study to compare cerebrospinal fluid (CSF) levels of neurogranin (Ng), Beta-site amyloid-precursor-protein cleaving enzyme1 (BACE1), Ng/BACE1 ratio and Amyloid-β 42/40 ratio, phosphorylated-tau and total-tau in LLD with (LLD AD) or without (LLD NoAD) AD pathology, predementia AD and normal controls (NC). We included 145 participants (NC = 41; predementia AD = 66 and LLD = 38). LLD comprised LLD AD (n = 16), LLD NoAD (n = 19), LLD with non-AD typical changes (n = 3, excluded). LLD AD (p ADJ < 0.05) and predementia AD (p ADJ < 0.0001) showed significantly higher Ng than NC. BACE1 and Ng/BACE1 ratio were altered similarly. Compared to LLD NoAD, LLD AD showed significantly higher Ng (p ADJ < 0.001), BACE1 (p ADJ < 0.05) and Ng/BACE1 ratio (p ADJ < 0.01). All groups had significantly lower Aβ 42/40 ratio than NC (predementia AD and LLD AD, p < 0.0001; LLD NoAD, p < 0.05). Both LLD groups performed similarly on tests of memory and executive function, but significantly poorer than NC. Synaptic function in LLD depended on AD pathology. LLD showed an association to Amyloid dysmetabolism. The LLD groups performed poorer cognitively than NC. LLD AD may be conceptualized as “predementia AD with depression”.

multidisciplinary sciences
Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares

Gwenn S. Smith,Clifford I. Workman,Hillary Protas,Yi Su,Alena Savonenko,Hiroto Kuwabara,Neda F. Gould,Michael Kraut,Jin Hui Joo,Ayon Nandi,Dimitri Avramopoulos,Eric M. Reiman,Kewei Chen

DOI: https://doi.org/10.1038/s41398-021-01539-9

2021-09-13

Translational Psychiatry

Abstract:Abstract Depression in late-life is associated with increased risk of cognitive decline and development of all-cause dementia. The neurobiology of late-life depression (LLD) may involve both neurochemical and neurodegenerative mechanisms that are common to depression and dementia. Transgenic amyloid mouse models show evidence of early degeneration of monoamine systems. Informed by these preclinical data, the hypotheses were tested that a spatial covariance pattern of higher beta-amyloid (Aβ) and lower serotonin transporter availability (5-HTT) in frontal, temporal, and parietal cortical regions would distinguish LLD patients from healthy controls and the expression of this pattern would be associated with greater depressive symptoms. Twenty un-medicated LLD patients who met DSM-V criteria for major depression and 20 healthy controls underwent PET imaging with radiotracers for Aβ ([ 11 C]-PiB) and 5-HTT ([ 11 C]-DASB). A voxel-based multi-modal partial least squares (mmPLS) algorithm was applied to the parametric PET images to determine the spatial covariance pattern between the two radiotracers. A spatial covariance pattern was identified, including higher Aβ in temporal, parietal and occipital cortices associated with lower 5-HTT in putamen, thalamus, amygdala, hippocampus and raphe nuclei (dorsal, medial and pontine), which distinguished LLD patients from controls. Greater expression of this pattern, reflected in summary 5-HTT/Aβ mmPLS subject scores, was associated with higher levels of depressive symptoms. The mmPLS method is a powerful approach to evaluate the synaptic changes associated with AD pathology. This spatial covariance pattern should be evaluated further to determine whether it represents a biological marker of antidepressant treatment response and/or cognitive decline in LLD patients.

psychiatry
Depression related cerebral pathology and its relationship with cognitive functioning: A systematic review

Alec Jamieson,Alicia M Goodwill,Mario Termine,Stephen Campbell,Cassandra Szoeke

DOI: https://doi.org/10.1016/j.jad.2019.03.042

2019-05-01

Abstract:Background: Depression's relationship with cerebral abnormalities and cognitive decline is temporally dynamic. Despite clear clinical utility, understanding depression's effect on cerebral structures, cognitive impairment and the interaction between these symptoms has had limited consideration. Methods: This review summarised studies examining a clinical depression diagnosis or validated scales measuring depressive symptoms, data concerning amyloid-beta (Aβ) levels, brain structure and function focusing on hippocampal alterations, or white matter hyperintensities (WMH), and at least one validated neuropsychological test. Online database searches of: PsycINFO, EMBASE, MEDLINE, and Scopus were conducted to identify potential articles. Results: While depression was consistently associated with cross-sectionally cognitive decline across multiple domains, the neuropathological basis of this dysfunction remained unclear. Hippocampal, frontal, and limbic dysfunction as well as cortical thinning, WMH, and Aβ burden all provide inconsistent findings, likely due to depression subtypes. The consistency of these findings additionally decreases when examining this relationship longitudinally, as these results are further confounded by pre-dementia states. The therapeutic interventions examined were more efficacious in the younger compared with the older samples, who were characterised by greater WMH and Aβ burden. Limitations: The limited number of longitudinal and interventional studies in addition to the heterogeneity of the samples restricts their generalisability. Conclusions: Symptomatological differences between early-onset and late-onset depression (EOD and LOD) appear crucial in understanding whether late-life depression is the primary or secondary source of cerebral pathology. Though severe cognitive impairments and clearer neuropathological underpinnings are more characteristic of LOD than EOD, the inconsistency of valid biomarkers remains problematic.
Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology

Kuan-Yi Wu,Kun-Ju Lin,Chia-Hsiang Chen,Chia-Yih Liu,Yi-Ming Wu,Cheng-Sheng Chen,Tzu-Chen Yen,Ing-Tsung Hsiao

DOI: https://doi.org/10.3389/fnagi.2022.857940

IF: 4.8

2022-05-26

Frontiers in Aging Neuroscience

Abstract:Cerebral amyloid-β (Aβ) depositions in depression in old age are controversial. A substantial proportion of individuals with late-life major depressive disorder (MDD) could be classified as having suspected non-Alzheimer’s disease pathophysiology (SNAP) by a negative test for the biomarker amyloid-β (Aβ−) but positive neurodegeneration (ND+). This study aimed to evaluate subthreshold Aβ loads in amyloid-negative MDD, particularly in SNAP MDD patients. This study included 46 amyloid-negative MDD patients: 23 SNAP (Aβ−/ND+) MDD and 23 Aβ−/ND− MDD, and 22 Aβ−/ND− control subjects. All subjects underwent 18 F-florbetapir PET, FDG-PET, and MRI. Regions of interest (ROIs) and voxel-wise group comparisons were performed with adjustment for age, gender, and level of education. The SNAP MDD patients exhibited significantly deceased 18 F-florbetapir uptakes in most cortical regions but not the parietal and precuneus cortex, as compared with the Aβ−/ND− MDD and control subjects (FDR correction, p < 0.05). No correlations of neuropsychological tests or depression characteristics with global cortical uptakes, but significant positive correlations between cognitive functions and adjusted hippocampal volumes among different groups were observed. The reduced Aβ depositions in the amyloid-negative MDD patients might be attributed mainly to the SNAP MDD patients. Our results indicated that meaningfully low amounts of subclinical Aβ might contain critical information on the non-amyloid-mediated pathogenesis.

neurosciences,geriatrics & gerontology,gerontology
Neuropsychiatric Profiles and Cerebral Amyloid Burden in Adults without Dementia

Eva Q. Gontrum,Emily W. Paolillo,Shannon Lee,Valentina Diaz,Alexander Ehrenberg,Rowan Saloner,Nidhi S. Mundada,Renaud La Joie,Gil Rabinovici,Joel H. Kramer,Kaitlin B. Casaletto

DOI: https://doi.org/10.1159/000538376

2024-03-21

Dementia and Geriatric Cognitive Disorders

Abstract:Introduction: We comprehensively evaluated how self- and informant-reported neuropsychiatric symptoms (NPS) were differentially associated with cerebral amyloid-beta (Aβ) PET levels in older adults without dementia. Methods: Two hundred and twenty-one participants (48% female, age = 73.4 years ± 8.4, Clinical Dementia Rating = 0 [ n = 184] or 0.5 [ n = 37]) underwent an Aβ-PET scan (florbetapir or PIB), comprehensive neuropsychological testing, and self-reported (Geriatric Depression Scale – 30 item [GDS-30]) and informant-reported interview (Neuropsychiatric Inventory Questionnaire [NPI-Q]) of NPS. Cerebral Aβ burden was quantified using centiloids (CL). NPI-Q and GDS-30 queried the presence of NPS within 4 subdomains and 6 subscales, respectively. Regression models examined the relationship between NPS and Aβ-PET CL. Results: Both higher self- and informant-reported NPS were associated with higher Aβ burden. Among specific NPI-Q subdomains, informant-reported changes in depression, anxiety, and irritability were all associated with higher Aβ-PET. Similarly, self-reported (GDS-30) subscales of depression, apathy, anxiety, and cognitive concern were associated with higher Aβ-PET. When simultaneously entered, only self-reported cognitive concern was associated with Aβ-PET in the GDS-30 model, while both informant-reported anxiety and depression were associated with Aβ-PET in the NPI-Q model. Clinical status moderated the association between self-reported NPS and Aβ-PET such that the positive relationship between self-perceived NPS and Aβ burden strengthened with increasing functional difficulties. Conclusions: In a cohort of older adults without dementia, both self- and informant-reported measures of global NPS, particularly patient-reported cognitive concerns and informant-reported anxiety and depression, corresponded with cerebral Aβ burden. NPS may appear early in the prodromal disease state and relate to initial AD proteinopathy burden, a relationship further exaggerated in those with greater clinical severity.

psychiatry,clinical neurology,geriatrics & gerontology,gerontology
Amyloid Burden and Depressive Symptom Trajectories in Older Adults at Risk of Developing Cognitive Decline

Ismael Conejero,Jonathan Dubois,Laure-Anne Gutierrez,Julien Delrieu,Christophe Arbus,Magalie Garcia,Jorge Lopez-Castroman,Philippe Courtet,Audrey Gabelle

DOI: https://doi.org/10.4088/JCP.20m13410

2021-08-03

Abstract:Objective: Little is known about the amyloid load impact on depressive symptoms or disorders, although it can modulate the cognitive trajectory in older adults. Here, we analyzed, in individuals at risk of Alzheimer's dementia, the relationship between amyloid load and depressive symptoms changes over time. Methods: This study included ≥ 70-year-old participants from the French Multidomain Alzheimer Preventive Trial (MAPT) (May 2008 to February 2011) who underwent brain amyloid load measurement by β-amyloid-[18F] florbetapir-PET at baseline and had spontaneous memory complaints and/or limitation in 1 instrumental activity of daily living or slow walking gait (N = 264). Symptoms of depression were measured with the Geriatric Depression Scale-15 items (GDS) at baseline and 6, 12, 24, and 36 months of follow-up. Four GDS factors were determined by principal component analysis (PCA): life satisfaction, level of apathy, self-esteem, and anxiety. Amyloid positive status was defined based on the amyloid load in 6 Alzheimer's dementia-related regions. Regional amyloid load was based on 3 dimensions defined by PCA. The longitudinal links between depressive symptomatology and amyloid load (ie, cortical AV45 and amyloid load dimensions) were analyzed using linear mixed-multivariate models. Results: At baseline, 11% of participants had depressive symptoms (GDS > 5) and 34% were amyloid-positive. The global amyloid load was not associated with worsening of the total GDS score but only with the impairment of self-esteem factor during the follow-up after adjustment for age, sex, education level, and drug intake, dementia, and Mini-Mental State Examination score (β = -0.029, 95% CI [-0.052 to -0.007], P = .003). Regional amyloid load in hippocampus and bilateral caudate nucleus protected significantly from self-esteem decrease during the 3-year follow-up. Conclusions: Although amyloid load shows no impact on GDS score in subjects at risk of Alzheimer's dementia, amyloid load may influence the progression of depressive dimension (self-esteem) with different effects according to the regional burden. Trial Registration: ClinicalTrials.gov identifier: NCT00672685.
Aortic debranching procedures to facilitate endografting.

M. Eskandari

DOI: https://doi.org/10.1177/1531003506295146

2006-12-01

Perspectives in Vascular Surgery

Abstract:Since approval of the Gore TAG device in 2005, endo-grafting of isolated descending thoracic aneurysms has been a welcome replacement to open surgery by many vascular and cardiac surgeons. Obvious constraints of this new technology are seal zones relative to adjacent brachiocephalic and visceral vessels. This is particularly important with regard to the more extensive thoracoabdominal aortic aneurysms. Although branched or fenestrated stent grafts have been used for such cases, these technically advanced devices are not available for general use and, therefore, many practitioners are left with few alternatives other than standard open repair. Some centers have tinkered with various forms of extra-anatomic bypass to lengthen seal zone sites and facilitate stent graft repair. The lack of uniformity and long-term data hamper acceptance of this approach. This review attempts to cull all available information on this technique from recent case reports and series published in the literature.
Interactions between mild depressive symptoms and amyloid pathology on the trajectory of neurodegeneration, cognitive decline, and risk of Alzheimer's disease

Xiao-Hui Zhang,Chen-Chen Tan,Ya-Wen Zheng,Xiao Ma,Jun-Nan Gong,Lan Tan,Wei Xu

DOI: https://doi.org/10.1016/j.jad.2024.08.235

IF: 6.533

2024-09-15

Journal of Affective Disorders

Abstract:Background Alzheimer's disease (AD) was driven by the interplay between modifiable environmental factors and β-amyloid (Aβ) pathology. We aimed to investigate the interaction effects of mild depressive symptoms (MDS) with Aβ on AD development. Methods Longitudinal data of 1746 non-demented adults (mean age = 73 years, female = 53 %, maximum = 10 years) were derived from the Alzheimer's Disease Neuroimaging Initiative cohort. MDS was separately defined by the baseline status, longitudinal latent class, and average intensity during follow-up. Amyloid-positive (A+) status was determined based on cerebrospinal fluid levels of β-amyloid. Regression models were employed to analyze the interactive effects of MDS with A+ on cognitive decline, neurodegeneration, and AD incidence. Results Individuals with both A+ status and MDS at baseline experienced the fastest neurodegeneration ( p < 0.01), cognitive decline ( p < 0.05), and a higher risk of developing AD (HR = 5.23, p < 0.001). Furthermore, A+ participants with the trajectory of increasing depressive symptoms demonstrated more pronounced neurodegeneration ( p < 0.001), cognitive decline ( p < 0.01), and elevated risk of AD (HR = 10.45, p < 0.001). Finally, A+ status in combination with a higher average intensity of depressive symptoms was associated with faster brain atrophy ( p < 0.01) and brain metabolism decline ( p < 0.05), cognitive decline (p < 0.05), and higher AD risk (HR = 13.99, p < 0.001). Conclusion These findings emphasized that the MDS-Aβ interaction relationship should be considered in risk stratification, prediction, and early management of neurodegeneration and cognitive decline in the pre-dementia stage.

psychiatry,clinical neurology
Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies

Emma L Twait,Maria Kamarioti,Inge M W Verberk,Charlotte E Teunissen,Astrid C J Nooyens,W M Monique Verschuren,Pieter Jelle Visser,Martijn Huisman,Almar A L Kok,P Eline Slagboom,Marian Beekman,Dina Vojinovic,Nico Lakenberg,M Arfan Ikram,Isabel K Schuurmans,Frank J Wolters,Justine E F Moonen,Lotte Gerritsen,Wiesje M van der Flier,Mirjam I Geerlings,NCDC Consortium

DOI: https://doi.org/10.1016/j.jagp.2024.03.004

Abstract:Background: Depressive symptoms are associated with an increased risk of Alzheimer's disease (AD). There has been a recent emergence in plasma biomarkers for AD pathophysiology, such as amyloid-beta (Aβ) and phosphorylated tau (p-tau), as well as for axonal damage (neurofilament light, NfL) and astrocytic activation (glial fibrillary acidic protein, GFAP). Hypothesizing that depressive symptoms may occur along the AD process, we investigated associations between plasma biomarkers of AD with depressive symptoms in individuals without dementia. Methods: A two-stage meta-analysis was performed on 2 clinic-based and 6 population-based cohorts (N = 7210) as part of the Netherlands Consortium of Dementia Cohorts. Plasma markers (Aβ42/40, p-tau181, NfL, and GFAP) were measured using Single Molecular Array (Simoa; Quanterix) assays. Depressive symptoms were measured with validated questionnaires. We estimated the cross-sectional association of each standardized plasma marker (determinants) with standardized depressive symptoms (outcome) using linear regressions, correcting for age, sex, education, and APOE ε4 allele presence, as well as subgrouping by sex and APOE ε4 allele. Effect estimates were entered into a random-effects meta-analysis. Results: Mean age of participants was 71 years. The prevalence of clinically relevant depressive symptoms ranged from 1% to 22%. None of the plasma markers were associated with depressive symptoms in the meta-analyses. However, NfL was associated with depressive symptoms only in APOE ε4 carriers (β 0.11; 95% CI: 0.05-0.17). Conclusions: Late-life depressive symptoms did not show an association to plasma biomarkers of AD pathology. However, in APOE ε4 allele carriers, a more profound role of neurodegeneration was suggested with depressive symptoms.
Dementia and depression: Biological connections with amyloid β protein

Helamã Moraes dos Santos,Amanda Gollo Bertollo,Maiqueli Eduarda Dama Mingoti,Roberta Eduarda Grolli,Kelli Maria Kreuz,Zuleide Maria Ignácio

DOI: https://doi.org/10.1111/bcpt.13996

2024-03-10

Basic & Clinical Pharmacology & Toxicology

Abstract:Amyloid‐β protein aggregates induce systemic chronic stress and strongly activate the hypothalamic–pituitary–adrenal (HPA) axis. This relation increases inflammation by dysregulating microglia activity and synapse failures, affecting diverse neurotransmission pathways. Besides, high reactive oxygen species (ROS) production establishes an oxidative stress state and subsequent neuronal death. All these processes, mediated by HPA axis products, result in the behavioural manifestations present in depression and dementia. Dementia is an umbrella term for a broad group of age‐associated neurodegenerative diseases. It is estimated that dementia affects 50 million people worldwide and that Alzheimer's disease (AD) is responsible for up to 75% of cases. Small extracellular senile plaques composed of filamentous aggregates of amyloid β (Aβ) protein tend to bind to neuronal receptors, affecting cholinergic, serotonergic, dopaminergic and noradrenergic neurotransmission, leading to neuroinflammation, among other pathophysiologic processes and subsequent neuronal death, followed by dementia. The amyloid cascade hypothesis points to a pathological process in the cleavage of the amyloid precursor protein (APP), resulting in pathological Aβ. There is a close relationship between the pathologies that lead to dementia and depression. It is estimated that depression is prevalent in up to 90% of individuals diagnosed with Parkinson's disease, with varying severity, and in 20 to 30% of cases of Alzheimer's disease. The hypothalamic pituitary adrenal (HPA) axis is the great intermediary between the pathophysiological mechanisms in neurodegenerative diseases and depression. This review discusses the role of Aβ protein in the pathophysiological mechanisms of dementia and depression, considering the HPA axis, neuroinflammation, oxidative stress, signalling pathways and neurotransmission.

pharmacology & pharmacy,toxicology
Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain

Didier Majou,Anne-Lise Dermenghem

DOI: https://doi.org/10.1016/j.brainres.2023.148681

IF: 3.61

2024-01-01

Brain Research

Abstract:In the early stages of sporadic Alzheimer's disease (SAD), there is a strong correlation between memory impairment and cortical levels of soluble amyloid-β peptide oligomers (Aβ). It has become clear that Aβ disrupt glutamatergic synaptic function, which can in turn lead to the characteristic cognitive deficits of SAD, but the actual pathways are still not well understood. This opinion article describes the pathogenic mechanisms underlying cerebral amyloidosis. These mechanisms are dependent on the amyloid precursor protein and concern the synthesis of Aβ peptides with competition between the non-amyloidogenic pathway and the amyloidogenic pathway (i.e. a competition between the ADAM10 and BACE1 enzymes), on the one hand, and the various processes of Aβ residue clearance, on the other hand. This clearance mobilizes both endopeptidases (NEP, and IDE) and removal transporters across the blood-brain barrier (LRP1, ABCB1, and RAGE). Lipidated ApoE also plays a major role in all processes. The disturbance of these pathways induces an accumulation of Aβ. The description of the mechanisms reveals two key molecules in particular: (i) free estradiol, which has genomic and non-genomic action, and (ii) free DHA as a preferential ligand of PPARα-RXRα and PPARɣ-RXRα heterodimers. DHA and free estradiol are also self-regulating, and act in synergy. When a certain level of chronic DHA and free estradiol deficiency is reached, a permanent imbalance is established in the central nervous system. The consequences of these deficits are revealed in particular by the presence of Aβ peptide deposits, as well as other markers of the etiology of SAD.

neurosciences
Amyloid Pathologies Modulate the Associations of Minimal Depressive Symptoms With Cognitive Impairments in Older Adults Without Dementia

Wei Xu,Wei Feng,Xue-Ning Shen,Yan-Lin Bi,Ya-Hui Ma,Jie-Qiong Li,Qiang Dong,Lan Tan,Jin-Tai Yu

DOI: https://doi.org/10.1016/j.biopsych.2020.07.004

IF: 12.81

2021-04-01

Biological Psychiatry

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>The relationship between depression and Alzheimer's disease (AD) is complex and still not well understood. We aimed to examine the roles of the AD core pathologies in modulating the associations of minimal depressive symptoms (MDS) with cognitive impairments.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A total of 721 participants, who had measures of cognition, depressive symptoms, and cerebrospinal fluid (CSF) AD biomarkers, were included from the Chinese Alzheimer's Biomarker and LifestylE (CABLE) study. The causal mediation analyses with 10,000 bootstrapped iterations were conducted to explore the mediation effects of AD pathologies on cognition. The Alzheimer's disease Neuroimaging Initiative (ADNI) was used 1) to replicate the mediation effects and 2) to examine the longitudinal relationships of MDS with amyloid pathology and incident AD risk.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>In CABLE, MDS was associated with poorer global cognition (p = 0.006) and higher amyloid burden as indicated by CSF amyloid markers (p < 0.0001). The influence of MDS on cognition was partially mediated by amyloid pathology (a maximum of 85%). The mediation effects were replicated in 725 non-demented elders (mean [SD] age, 73.5 [6.9] years, 301 [42%] female) in ADNI, such that the mediation percentage varied from 10 to 30% for general cognition, memory, and executive functions. Longitudinal analyses revealed a bidirectional relationship between MDS and amyloid pathology (p = 0.01). MDS was associated with 83% increased risk of developing AD dementia (HR = 1.83, p < 0.01).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Overall, amyloid pathology might partially mediate and magnify the influences of MDS on cognitive impairments and AD risk.</p>

neurosciences,psychiatry
Depression in Alzheimer's disease: epidemiology, mechanisms, and treatment

Yu-Yuan Huang,Yi-Han Gan,Liu Yang,Wei Cheng,Jin-Tai Yu

DOI: https://doi.org/10.1016/j.biopsych.2023.10.008

IF: 12.81

2023-10-21

Biological Psychiatry

Abstract:Depression and Alzheimer's disease (AD) are substantial public health concerns. In the past decades, a link between two disease entities has received extensive acknowledgment, yet the complex nature of this relationship has demanded further clarification. Some evidence indicates that mid-life depression may be an AD risk factor, while a chronic course of depression in late life may be a precursor to or symptom of dementia. Recently, multiple pathophysiological mechanisms have been proposed to underlie the bidirectional relationship between depression and AD, including genetic predisposition, immune dysregulation, the accumulation of AD-related biomarkers (e.g., amyloid beta and tau), and alterations in brain structure. That being the case, numerous therapeutic approaches, such as pharmacology treatments, psychotherapy, and lifestyle interventions, have been suggested as potential means of interfering with these pathways. However, the current literature on this topic remains fragmented and lacks a comprehensive review characterizing the association between depression and AD. In this review, we aim to address these gaps by providing an overview of the co-occurrence and temporal relationship between depression and AD, as well as exploring their underlying mechanisms. We also examine the current therapeutic regimens for depression and their implications for AD management, and outline key challenges facing the field.

neurosciences,psychiatry
Associations of Subsyndromal Symptomatic Depression with Cognitive Decline and Brain Atrophy in Elderly Individuals without Dementia: A Longitudinal Study

Zhao Zhang,Feng Wei,Xue-Ning Shen,Ya-Hui Ma,Ke-Liang Chen,Qiang Dong,Lan Tan,Jin-Tai Yu,Alzheimer's Disease Neuroimaging Initiative

DOI: https://doi.org/10.1016/j.jad.2020.05.097

IF: 6.533

2020-09-01

Journal of Affective Disorders

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Subsyndromal symptomatic depression (SSD) is prevalent in older adults. However, it remains unclear whether there are effects of SSD on brain aging outcomes (cognition and brain structures), especially in the presence of Alzheimer's Disease (AD) pathology.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A total of 1,188 adults without dementia were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Participants with SSD were measured using the 15-item Geriatric Depression Scale (GDS-15). In multivariable models, the cross-sectional and longitudinal associations of SSD with brain aging outcomes were explored. We further evaluated whether baseline amyloid-β (Aβ) load modifies the relations between SSD and brain aging outcomes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>SSD at baseline was associated with significantly longitudinal decline in cognition and displayed significantly accelerated atrophy in hippocampus (β = –29.53, p = 0.001) and middle temporal gyrus (β = – 77.82, p = 0.006) among all participants and Aβ-Positive individuals. SSD interacted with baseline Aβ load in predicting longitudinal decline in Mini Mental State Examination (MMSE) (β = – 0.327, p = 0.023), episodic memory (β = –0.065, p = 0.004) and increase in Alzheimer's Disease Assessment Scale Cognition 13-item scale (ADAS-cog13) (β = 0.754, p = 0.026).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Limitations</h3><p>Our study didn't look at AD diagnosis but Aβ status.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Our findings suggested that older people without dementia with both SSD and a high level of Aβ load may have higher risk of cognitive deterioration and brain atrophy. Therapeutic mitigation of depressive symptoms, especially in those with abnormal Aβ levels, may help delay progressive decline in cognition.</p>

psychiatry,clinical neurology
Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies

R. Scott Mackin,Emma Rhodes,Michelle Kassel,Maria Kryza-Lacombe,Emily Burns,David Bickford,Ruth Morin,Duygu Tosun,Susan Landau,Meryl A. Butters,Paul Aisen,Rema Raman,Andrew J. Saykin,Arthur Toga,Robert Koeppe,Clifford Jack,Michael W. Weiner,Craig Nelson,Philip S. Insel

DOI: https://doi.org/10.1038/s41380-024-02677-4

IF: 11

2024-11-08

Molecular Psychiatry

Abstract:This study was conducted to clarify patterns of cortico-limbic volume abnormalities in late life depression (LLD) relative to non-depressed (ND) adults matched for amyloid β (Aβ) deposition and to evaluate the relationship of volume abnormalities with cognitive performance. Participants included 116 LLD and 226 ND. Classification accuracy of LLD status was estimated using area under the receiver operator characteristic curve. Twenty-one percent of LLD and ND participants were Aβ positive and the groups did not differ on white matter hyperintensity volume (WMH (logscale); β = 0.12, p = 0.28). Compared to ND, the LLD group exhibited significantly lower bilateral volume in the lateral orbitofrontal cortex, hippocampus, accumbens area, superior temporal lobe, temporal pole, and amygdala after multiple comparison correction ( p < 0.009 for all). Cortico-limbic volumes significantly improved classification of LLD beyond demographic characteristics, Aβ status, and WMH (AUC Vol = 0.71, AUC WMH , Aβ = 0.62, AUC difference, 0.09 [0.03 to 0.15]). LLD exhibited poorer performance on measures of global cognition, set shifting, and verbal learning and memory relative to ND. Cognitive function was positively associated with cortico-limbic volumes and these relationships did not differ by group. Secondary analyses with an ND sample additionally matched for Mild Cognitive Impairment (MCI) diagnosis showed a similar but attenuated pattern of volume abnormalities. Overall, our results support LLD as being associated with cortico-limbic volume abnormalities that are distinct from Aβ and white matter pathologies and that these volume abnormalities are important factors associated with cognitive dysfunction in LLD.

biochemistry & molecular biology,neurosciences,psychiatry
TIMP‐1 as candidate gene for embryo survival in two divergent lines selected for uterine capacity in rabbits

J. Estellé,Y. Sastre,M. Merchán,R. Peiró,M. A. Santacreu,J. Folch

DOI: https://doi.org/10.1002/mrd.20476

2006-06-01

Molecular Reproduction and Development

Abstract:Selection on uterine capacity has been used in animal breeding as a way to improve the litter size. A divergent selection experiment for uterine capacity was performed in rabbits during ten generations. After the first generations of selection, large differences in number of implanted embryos were obtained between high and low lines. The major part of the differences between lines was due to embryo survival. A segregation analysis suggested the presence of a major gene affecting the reproductive traits. The objective of this work was to test the TIMP‐1 gene as a candidate gene for embryo survival in rabbits since it stands up as a target for the investigation of reproductive problems in humans. We have analyzed the parental generation of a F2 cross which consists of 8 and 14 animals from the high and low uterine capacity lines, respectively. The rabbit TIMP‐1 gene structure and sequence has been determined, including the proximal promoter region. Despite of the absence of polymorphism between lines in the screened regions (CDS, proximal promoter, exon 1, intron 1, and exon 2), a real‐time RT‐PCR quantification of the TIMP‐1 mRNA in oviduct has shown significant differences between high and low lines at 62 hr of gestation, just when rabbit embryos are located in the oviduct, postulating TIMP‐1 as an interesting candidate gene to be involved in the phenotypic differences between the two rabbit lines. Mol. Reprod. Dev. © 2006 Wiley‐Liss, Inc.
Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline

Yi-Chia Wei,Yi-Chia Kung,Chemin Lin,Chun-Hung Yeh,Pin-Yuan Chen,Wen-Yi Huang,Yu-Chiau Shyu,Ching-Po Lin,Chih-Ken Chen

DOI: https://doi.org/10.1038/s41398-024-03049-w

2024-08-18

Translational Psychiatry

Abstract:Older adults with major depressive disorder (MDD) or early cognitive decline during the subjective cognitive decline (SCD) stage may exhibit neuropsychiatric symptoms such as anxiety, depression, and subtle cognitive impairment. The clinicopathological features and biological mechanisms of MDD differ from those of SCD among older adults; these conditions thus require different treatment strategies. This study enrolled 82 participants above 50 years old with normal cognitive levels from the communities to examine biomarker–behavior correlations between MDD ( n = 23) and SCD ( n = 23) relative to a normal control (NC) group ( n = 36). Multidomain assessments were performed for all participants, including immunomagnetic reduction tests to detect plasma beta-amyloid (Aβ), total tau (Tau), phosphorylated tau-181 (p-Tau181), neurofilament light chain, and glial fibrillary acidic protein (GFAP). This study observed that depressive symptoms in MDD were associated with amyloid pathology (plasma Aβ40 vs. HADS-D: R = 0.45, p = 0.031; Aβ42/Aβ40 vs. HADS-D: R = −0.47, p = 0.024), which was not observed in the NC (group difference p < 0.05). Moreover, cognitive decline in MDD was distinguished by a mixed neurodegenerative process involving amyloid (plasma Aβ42 vs. facial memory test: R = 0.48, p = 0.025), tau (Tau/Aβ42 vs. digit symbol substitution test (DSST): R = −0.53, p = 0.01), and astrocytic injury (plasma GFAP vs. Montreal cognitive assessment score: R = −0.44, p = 0.038; plasma GFAP vs. DSST: R = −0.52, p = 0.014), findings that did not apply to the NC (group difference p < 0.05). Moreover, this study revealed different biomarker–behavior correlations between individuals with SCD and the NC. Compared with the NC, cognitive decline in the SCD group might be unrelated to amyloid pathology and instead might be early manifestations of tau pathology. This study underscores the difference in clinicopathological features between MDD and SCD among older adults, which differ from those of the NC. These findings enhance our understanding of the mechanisms underlying MDD and SCD in older individuals.

psychiatry

Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema

A renal transplant patient with a solitary plasmacytoma in the oral cavity.

Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis

Gastric cytology.

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression

Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares

Depression related cerebral pathology and its relationship with cognitive functioning: A systematic review

Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology

Neuropsychiatric Profiles and Cerebral Amyloid Burden in Adults without Dementia

Amyloid Burden and Depressive Symptom Trajectories in Older Adults at Risk of Developing Cognitive Decline

Aortic debranching procedures to facilitate endografting.

Interactions between mild depressive symptoms and amyloid pathology on the trajectory of neurodegeneration, cognitive decline, and risk of Alzheimer's disease

Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies

Dementia and depression: Biological connections with amyloid β protein

Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain

Amyloid Pathologies Modulate the Associations of Minimal Depressive Symptoms With Cognitive Impairments in Older Adults Without Dementia

Depression in Alzheimer's disease: epidemiology, mechanisms, and treatment

Associations of Subsyndromal Symptomatic Depression with Cognitive Decline and Brain Atrophy in Elderly Individuals without Dementia: A Longitudinal Study

Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies

TIMP‐1 as candidate gene for embryo survival in two divergent lines selected for uterine capacity in rabbits

Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline